The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2023Evaluation of a Digital Therapeutics (DTx) Mobile App and Algorithm for Personalized Medication and Treatment Plan Optimization for People with Parkinson’s Disease
Study Rationale: People with Parkinson’s disease (PD) have few options for keeping their symptoms under control. An app that could automatically monitor PD symptoms, like tremors, could allow users to...
-
Translational Pipeline Program, 2022Prevention of Dementia in GBA-associated Parkinson’s Disease
Study Rationale: Whereas motor symptoms can be well controlled by dopamine-enhancing drugs and deep brain stimulation, dementia represents a key milestone in the course of Parkinson’s disease (PD)...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Dopamine D1 Receptor for a Treatment of Parkinson’s Disease with Minimal L-DOPA-induced Dyskinesia
Study Rationale: L-DOPA is the primary drug used for treating the mobility loss that occurs in Parkinson’s disease (PD) due to decreases in dopamine. Although L-DOPA enhances mobility, chronic...
-
Translational Pipeline Program, 2023Evaluation of Glunomab, a Novel Immunotherapy for the Treatment of Parkinson’s Disease
Study Rationale: Glunomab is a monoclonal antibody that inhibits a toxic interaction between two proteins recently determined to be involved in the pathology of Parkinson’s disease (PD). Because its...
-
Research Grant, 2022Evaluation of Assessments Made by Digital Health Technology
Study Rationale: The development of drugs that can slow or halt the progression of Parkinson’s disease (PD) can be expensive and take a long time. Although there are many promising new therapeutics in...
-
Research Grant, 2023Validation of Gap Junction Proteins as a New Therapeutic Target for Impeding the Cell-to-cell Spread of Alpha-synuclein in Parkinson’s Disease and Related Synucleinopathies
Study Rationale:The gap junctions that directly connect one cell with its neighbor have recently been implicated in the transfer of alpha-synuclein pathology associated with Parkinson’s disease (PD)...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.